5 Gene Editing Stocks With the Best Long-Term Potential

4. Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Number of Hedge Fund Holders: 39

Intellia Therapeutics, Inc. (NASDAQ:NTLA) shares jumped earlier this month after Canaccord Genuity started covering the stock with a Buy rating and a $66 price target. The firm cited Intellia Therapeutics, Inc. (NASDAQ:NTLA)’s expertise in the CRISPR-Cas9 gene editing technology. Canaccord’s analyst Whitney Ijem highlighted Intellia Therapeutics, Inc. (NASDAQ:NTLA)’s different approach in in-vivo gene editing and said that Intellia’s “methodical approach has paid off.”

Of the 943 hedge funds tracked by Insider Monkey, 39 hedge funds tracked by Insider Monkey had stakes in Intellia Therapeutics, Inc. (NASDAQ:NTLA). The total worth of these stakes was $690 million. The biggest stakeholder of Intellia Therapeutics, Inc. (NASDAQ:NTLA) was Catherine D. Wood’s ARK Investment Management which owns a $329 million stake.